
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
30 March 2022
One Cancer Voice 10-Year Cancer Plan Consensus Statement
We have joined with 53 cancer charities to speak with One Cancer Voice and publish 10 tests that the Government’s new 10-year Cancer Plan must meet if it is to be successful.
15 June 2018
Nick Boles’ Ambulatory Care Unit opening speech
An edited extract of the speech Nick Boles MP made at the official opening of the Leukaemia UK Ambulatory Care Unit.
19 December 2023
Beloved actor who beat leukaemia now fronting charity TV ad to help raise vital funds
83-year-old actor Richard Tate will appear on screens from 26th December onwards to support Leukaemia UK’s call for legacy pledges (otherwise known as gifts in Wills), after surviving leukaemia thanks…
10 August 2022
Leukaemia UK unveils an exciting new brand
Leukaemia UK has today revealed a bold new look and feel that embodies the charity’s ambitious new strategy and our desire to be a greater force for change. Bringing together…